When and how should copeptin be measured to differentiate central from nephrogenic diabetes insipidus in a patient with unexplained polyuria‑polydipsia?

When and How to Check Copeptin for Diabetes Insipidus

In adults with unexplained polyuria-polydipsia, measure baseline plasma copeptin first: levels >21.4 pmol/L are diagnostic for nephrogenic diabetes insipidus without further testing needed, while levels <21.4 pmol/L require stimulated copeptin measurement (via hypertonic saline or arginine infusion) to differentiate central diabetes insipidus from primary polydipsia. 1

Diagnostic Algorithm

Step 1: Initial Assessment and Baseline Copeptin

When you encounter a patient with polyuria and polydipsia, first confirm the syndrome with:

• Serum sodium and osmolality
• Urine osmolality (typically <200 mOsm/kg H₂O in diabetes insipidus)
• Baseline plasma copeptin measurement (no prior water deprivation needed)

Step 2: Interpret Baseline Copeptin

If baseline copeptin >21.4 pmol/L:

• Diagnosis: Nephrogenic diabetes insipidus 1
• No additional testing required
• This cutoff has 100% sensitivity and specificity in adults 1
• These values are significantly higher than other polyuric disorders, making the diagnosis unequivocal 1

If baseline copeptin <21.4 pmol/L:

• Proceed to stimulated copeptin testing to differentiate central diabetes insipidus from primary polydipsia 1

Step 3: Stimulated Copeptin Testing (When Baseline <21.4 pmol/L)

You have two validated options:

Option A: Hypertonic Saline Infusion Test (Most Accurate)

• Protocol: Infuse 3% hypertonic saline until serum sodium reaches ≥150 mmol/L 2
• Measure copeptin at this sodium threshold
• Interpretation:
  • Copeptin >4.9 pmol/L = Primary polydipsia
  • Copeptin ≤4.9 pmol/L = Central diabetes insipidus
• Diagnostic accuracy: 96.5% overall, superior to water deprivation test (76.6%) 2
• Critical requirement: Close sodium monitoring with rapid laboratory turnaround to prevent dangerous hypernatremia 1, 3

Option B: Arginine Infusion Test (Safer Alternative)

• Stimulates copeptin release without inducing hypernatremia 1, 3
• Shorter test duration and safer profile
• Same copeptin cutoff of 4.9 pmol/L applies 3

Key Clinical Nuances

Why Copeptin Over Traditional Testing

The traditional water deprivation test has only 76.6% diagnostic accuracy compared to 96.5% for copeptin-based testing 2. The copeptin approach:

• Avoids the cumbersome, prolonged water deprivation protocol
• Eliminates the technical challenges of measuring unstable AVP directly
• Reduces misdiagnosis, particularly in partial central diabetes insipidus vs. primary polydipsia 4, 5

Pediatric Considerations

Important caveat: The evidence for copeptin cutoffs in children is limited 1. While one pediatric study suggested a cutoff of 3.53 pmol/L for central diabetes insipidus 6, the 2025 international consensus states that "only a few reports have evaluated the diagnostic values of plasma copeptin in paediatric polyuric disorders" 1. Exercise caution when applying adult cutoffs to children.

When Genetic Testing Supersedes Copeptin

Genetic testing should be performed first when:

• Presentation occurs in infancy or early childhood
• Family history suggests inherited diabetes insipidus
• Clinical picture strongly suggests congenital nephrogenic diabetes insipidus

Genetic testing (multigene panel including AVPR2, AQP2, and AVP genes) provides definitive diagnosis and avoids potentially harmful diagnostic procedures 1. Copeptin testing is recommended only when genetic testing is unavailable or inconclusive (5-10% of cases) 1.

Common Pitfalls to Avoid

1. Don't perform water deprivation testing if copeptin is available - it's less accurate and more burdensome 2

2. Don't use copeptin for hyponatremia/SIAD diagnosis - copeptin levels overlap widely in hyponatremia and are not diagnostically useful for syndrome of inappropriate antidiuresis 5

3. Don't skip sodium monitoring during hypertonic saline infusion - requires close supervision to prevent dangerous hypernatremia 1, 3

4. Don't rely on unstimulated copeptin alone (except for nephrogenic diabetes insipidus) - baseline levels overlap between central diabetes insipidus and primary polydipsia, requiring stimulation testing 4, 7

5. Don't forget that copeptin is a surrogate marker - it's released in equimolar 1:1 ratio with AVP, making it a stable, reliable alternative to direct AVP measurement 1, 3, 5